Newborn screening for cystic fibrosis - The parent perspective. by Rueegg, Corina S et al.
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
74
82
0 
| 
do
wn
lo
ad
ed
: 
6.
1.
20
20Original Article☆ Previous publicat
June 11–14, 2014, (R
(Suppl. 2):48s.), and
Newborn screening f
A partial version of
journals:
- Rueegg CS, et
- Rueegg CS, et
⁎ Corresponding au
35 07; fax: +41 31 6
E-mail address: c
1 Both authors hav
2 Members of the S
(Lucerne); Sabina G
Isabelle Rochat (Laus
Daniel Trachsel (Bas
http://dx.doi.org/10.1
1569-1993/© 2015 Ewww.elsevier.com/locate/jcf
Journal of Cystic Fibrosis 15 (2016) 443–451Newborn screening for cystic ﬁbrosis — The parent perspective☆Corina S. Rueegg a,b,1, Jürg Barben c,1, Gaudenz M. Hafen d, Alexander Moeller e, Maja Jurca a,
Ralph Fingerhut f, Claudia E. Kuehni a,⁎, The Swiss Cystic Fibrosis Screening Group 2
a Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
b Department of Health Sciences and Health Policy, University of Lucerne, Lucerne, Switzerland
c Division of Pediatric Pulmonology, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland
d Department of Pediatrics, Respiratory Unit, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
e Division of Respiratory Medicine, University Children's Hospital of Zurich, Zurich, Switzerland
f Swiss Newborn Screening Laboratory, University Children's Hospital Zurich, Zurich, Switzerland
Received 21 August 2015; revised 30 November 2015; accepted 1 December 2015
Available online 29 December 2015Abstract
Background: Newborn screening for CF started 01/2011 in Switzerland. We investigated the parents' opinions about the information received,
their feelings, and overall approval of the screening.
Methods: This is a prospective questionnaire survey of all parents of positively screened children. Parents were phoned by CF-centres and invited
for diagnostic investigations. They completed a questionnaire after the visit to the CF-centre.
Results: From 2011–2013, 246 families received the questionnaire and 138 (56%) replied. Of these 77 (60%) found the information received at
birth satisfactory; 124 (91%) found the information provided in the CF-centre satisfactory. Most parents (n = 98, 78%) felt troubled or anxious
when the CF-centre called, 51 (38%) remained anxious after the visit. Most parents (n = 122; 88%) were satisﬁed with the screening, 4 (3%) were
not, and 12 (9%) were unsure.
Conclusions: The smooth organisation of the screening process, with personal information by a CF specialist and short delays between this
information and the ﬁnal diagnostic testing, might have contributed to reduce anxiety among parents. Most families were grateful that their child
had been screened, and are happy with the process.
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Newborn screening (NBS) for cystic fibrosis (CF) has many
benefits. When CF is diagnosed and treated early, infant's food
intake and digestion, growth, cognitive development and lung
function can be improved, and exacerbations and hospitaliza-
tions decreased [1–3]. However, one of the drawbacks of NBS
is that it can cause anxiety and distress to parents of children
with positive screening results. After a positive screening,
parents go through a phase of uncertainty and anxiety until the
diagnosis of CF is confirmed or rejected [4–6]. Parents may
also remain concerned after a false-positive screening result,
even if CF is ruled out [7–11]. A second possible drawback is
that NBS may identify CF-carriers, or children with rare and/or
mild CF-mutations, whose further clinical course cannot be
clearly predicted and who might be asymptomatic for years
[7,12]. This may lead to unnecessary medicalization and impair
mother–child bonding [5,9,13,14].
Several investigations have shown that distress can be
reduced if parents are properly informed, and if the period
between receiving the positive screening result and confirma-
tion through diagnostic evaluation in a specialised clinic is kept
short [10,15–22]. Other studies have investigated the opinion
of unaffected parents toward genetic screening in general or
screening for CF [23–26]. But we are not aware of a neonatal
screening programme for CF, which, at the time of its
introduction, has assessed prospectively the feedback of parents
on a broad range of factors relevant for the screening process.
Feedback from parents who have gone through the whole
process could help to identify weaknesses of the current
screening procedures and show areas that need further research.
In Switzerland, CF-NBS was implemented nation-wide in
January 2011 [27–29]. Along with its introduction, we wanted
to evaluate and assess the opinions of affected parents in
relation to relevant steps of the screening process. The results of
this evaluation will help to further improve the screening
process in Switzerland, and might provide useful information
for other countries that plan to establish or adapt their screening
procedures for CF.
In particular, this study aimed to investigate: 1) the
information about NBS provided to parents at birth; 2) parental
satisfaction with the information they received during the
CF-NBS; 3) their feelings at different stages of the CF-NBS;
and, 4) their overall approval of the CF-NBS. Furthermore, we
investigated the association of socio-demographic and clinical
factors with information provision, parents' satisfaction with
the information received, parents' feelings during the screening
and parents' approval of the screening.
2. Patients and methods
2.1. Newborn screening in Switzerland
Screening for CF was implemented in the regular NBS
programme. In Switzerland, most women give birth in a
hospital; few give birth at home or in special birthing centres.
Before or after delivery, all families must be informed about theNBS and receive a brochure about the screening, including a
section on cystic fibrosis (INFO 1&2 in Fig. 1; brochure
available under http://www.neoscreening.ch/en/download4.
htm). By default, all children are screened, unless parents
actively refuse to participate (possibility to opt out; done by
about 5–10 families per year). The NBS requires a midwife or a
nurse to take a heel-prick blood sample on filter paper (Guthrie
Card) on the 4th day of life. The Guthrie Cards are sent to the
national Swiss Newborn Screening Laboratory (SNSL) in
Zurich for analysis.
2.2. Procedure of the Swiss CF-NBS
The CF-NBS has two parts (Fig. 1) [28,29]. The first is the
screening part, done in the SNSL. The second, the diagnostic
part, is done in dedicated CF-centres.
2.2.1. Screening part
In the SNSL, immunoreactive trypsinogen (IRT) is measured in
the dried blood-spot of the Guthrie Card. If IRT is ≥50 ng/ml
(≥99.2 percentile), the sample is genetically screened for a limited
number of mutations [28,29]. If one or two mutations are found,
the child of the sample is considered screening positive. If no
mutations are found, and the initial IRT is≥60 ng/ml, the midwife
or family physician is asked to recall the family to perform another
heel-prick test within 2–3 weeks. If the IRT of the second test is
≥50 ng/ml, the child of the sample is also considered as screening
positive. All positively screened children are notified by phone
from the SNSL to the CF-specialist of the respective family's
nearest CF-centre.
2.2.2. Diagnostic part
The responsible CF-specialist of the centre calls the parents
of children with positive screening result, informs them (INFO
3 in Fig. 1), and invites them for diagnostic evaluation (sweat
test) on the next day. He/She tells the parents, that the screening
result for CF was positive and needs further diagnostic
investigation to find out if it reflects true CF disease, or the
result is false positive. If the parents have more questions
regarding CF, the CF specialist takes time to answer them on
the phone but emphasises, that they will discuss these questions
in more detail during the visit.
If the sweat test is positive (Cl− ≥ 60 mmol/l) or borderline
(Cl− = 30–59 mmol/l), a blood sample is taken, after obtaining
written informed consent, for detailed genetic analysis. Parents
are informed by the CF specialist about the test results and the
disease (INFO 4 in Fig. 1), and appropriate treatment is
initiated.
If the sweat test is negative (Cl− ≤ 30 mmol/l), parents are
also informed by the CF-specialist in person on the same day.
They are being explained that their child is healthy, but could
be a CF carrier. In addition, they receive an information leaflet
that explains in detail the meaning of a positive screening result
with a normal sweat test result (INFO 4 in Fig. 1). The same
leaflet is sent to their family doctor or paediatrician.
All parents are given an information sheet about voluntary
genetic counselling.
Fig. 1. Procedure of the Swiss newborn screening for CF. Fig. 1 shows the general procedure of the Swiss newborn screening for CF with a focus on the interaction
with parents. It starts from the birth of the child to the final diagnosis. The detailed algorithm of the Swiss newborn screening for CF was published elsewhere
(Ref. [28]). Abbreviations: AA, Aarau; BE, Bern; BS, Basel; CF, Cystic Fibrosis; GE, Geneva; LS, Lausanne; LU, Lucerne; SG, St. Gallen; ZH, Zurich.
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The screening results of all positively screened children are
entered into a central project database by SNSL staff. After the
diagnostic evaluation, clinical data and diagnostic test results areentered on a form by the CF-physician, sent to the central database
at the University of Bern and then entered by a central data
manager. For this analysis, we used the following information
from the database: child's birthdate; sex; responsible CF-centre
446 C.S. Rueegg et al. / Journal of Cystic Fibrosis 15 (2016) 443–451(categorised as large if they diagnosed N30 patients in 3 years);
date of phone call to parents; date of visit to the CF-centre; final
diagnosis; and, date of genetically-confirmed diagnosis.
2.2.4. Parental questionnaire
At the visit in the CF-centre, all parents received a questionnaire
(4 pages, 25 items) in German (Appendix I), French or Italian,
with a prepaid return envelope. The questionnaire was developed
by clinicians (CF specialists) and epidemiologists to evaluate the
new CF-NBS in Switzerland with specific questions related to the
following topics: 1) the information received during the screening
and the satisfaction with the information received; 2) parent's
knowledge on CF prior to the screening; 3) parent's feelings during
the screening procedure; 4) parent's overall opinion on the
screening; 5) type of birth institution. In addition, we assessed
socio-demographic characteristics of parents with standardised
questions from the Swiss Census (language, education, migration
background, number of children in the family) [30]. The
questionnaire was pilot tested by members and relatives of the
study team and translated by a professional translator into French
and Italian. Parents completed the questionnaire at home, after the
visit. At that point, their certainty about the final diagnosis
depended on the sweat test result (conclusive or inconclusive).
Information provision
We asked parents whether or not, and from whom they had
received the information brochure or any orally conveyed
information on the NBS, before or after birth. Parents could
choose from a list of possible specialists or add another person
in free text.
Satisfaction with the information
Parents could indicate, for each type of information (INFO
1–4 in Fig. 1), if it had satisfied them. If not, they could explain
why in an open format.
Parents' feelings
Parents could describe how they felt after the phone call from
the CF-centre, and after the diagnostic evaluation in the CF-centre.
They could choose between the answer categories “optimistic”,
“calm”, “troubled”, “very troubled”, or add their own description of
their feelings. We categorised answers into a binary variable
(“calm & optimistic” vs. “troubled & anxious”) for the analysis.
Overall approval
We asked parents if they were glad that their child had been
screened (Yes/No). They could state why they approved or
disapproved of the screening in an open format. They were also
asked if they would change the screening procedure (Yes/No)
and, if so, what they would change in an open format.
2.3. Statistical analysis
We used descriptive statistics (proportions and 95% confidence
intervals (CI)) to describe the information provision to parents,
parents' satisfaction with the information received, parents'
feelings and their approval of the screening. To summariseindividual open format statements, we manually combined
statements of the same meaning into groups of similar content.
The classificationwas done by one author (CSR); ambiguities were
solved in discussion with CEK and JB. Because the final diagnosis
could be a strong predictor of parents' feelings and approval of the
screening, we stratified the analysis by final diagnosis (CF vs. no
CF). We used univariable logistic regression models to assess the
association of socio-demographic and clinical factors with parents'
satisfaction with the information received, parents' feelings during
the screening and parents' approval of the screening. We used
univariable logistic regression models to investigate whether
information provision differed by type of birth institution or
screening year.
3. Results
3.1. Study population
Within the first 3 years of the Swiss CF-NBS, 253,346 IRT
analyses were performed and 260 children with a positive
screening result were referred to a CF-centre. Of these, 246
received a questionnaire and 138 returned it (response rate =
56%; Supplemental Fig. 1). Responders were more often of
Swiss origin (p b 0.001) and had a child with CF (p = 0.023;
Table 1), but they were otherwise similar.
In 54% (n = 74) of responders, the screened infant was their
first-born; 52% (n = 71) had heard of CF before; and, 17%
(n = 23) knew someone with CF. Most children were born in a
hospital (94%; n = 129). Finally, 47 (34%) were diagnosed
with CF, 2 (2%) with a CFSPID (CF Screen Positive,
Inconclusive Diagnosis), and CF was ruled out in 89 (65%).
The mean age of infants seen at the CF-centre was 22 days. On
average, one day passed between the telephone call to parents
and their visit in the CF-centre. On average, questionnaires
arrived 11 days after the clinic visit.
3.2. Aim 1: information provision at birth
Of 138 parents, 13 (11%) remembered that they received the
NBS information brochure before birth, 76 (58%) remembered
receiving it after birth (Supplemental Table 1); 26 (20%)
remembered receiving information orally before birth, and 106
(84%) remember receiving oral information after birth. Both
brochures and oral information were most commonly received
from nurses or midwives. Information was more often provided to
parents of children born in birthing centres or at home
(Supplemental Table 2). The rate at which information was
provided did not change over the three years of the screening.
3.3. Aim 2: satisfaction with information provided
Of the 81 parents who remembered the brochure, 69 (85%)
thought it was good (Fig. 2; INFO 1&2 in Fig. 1). The oral
information received at birth was satisfactory to 77 parents
(60%; INFO 1&2 in Fig. 1). The information given by the
CF-physician over the telephone was satisfactory to 100 (74%;
INFO 3 in Fig. 1) parents, and the information given personally
Table 1
Characteristics of parents responding and not responding to the CF newborn screening questionnaire.
Responders (n = 138) Non-responders (n = 108)
n % a n %a p-value b
Child's demographic characteristics
Child's year of birth 0.495
2011 48 35 36 33
2012 47 34 31 29
2013 43 31 41 38
Child's sex 0.706
Male 65 47 53 50
Female 73 53 54 50
Family's socio-demographic characteristics
Spoken language n.a. c
Swiss German 92 68 n.a. c n.a. c
French 36 27
Italian 7 5
Highest parental education n.a. c
Primary 47 35 n.a. c n.a. c
Secondary 24 18
Tertiary 64 47
Country of origin of the mother b0.001
Switzerland 95 69 50 53
Other 42 31 45 47
Number of children n.a. c
Screened child is the first child 74 54 n.a. c n.a. c
Screened child has older siblings 64 46
Family has heard of CF before n.a. c
No 71 52 n.a. c n.a. c
Yes 67 48
Family knows someone with CF n.a. c
No 115 83 n.a. c n.a. c
Yes 23 17
Clinical characteristics
Birth institution 0.195
Hospital 129 94 94 88
Birthing centre 2 2 1 1
Home 7 5 12 11
Type of CF-centre 0.990
Small 64 46 50 46
Large (N30 patients diagnosed in 3 years) 74 54 58 54
Child's final diagnosis 0.023
No CF 89 65 77 71
CF 47 34 24 22
CFSPID 2 2 7 7
Median SD Median SD p-value d
Time variables
Time between telephone and clinic visit (d) 1.0 1.8 1.0 2.3 0.168
Age at visit in the CF-centre (d) 22.0 12.3 23.0 33.2 0.136
Time between clinic visit and questionnaire reply (d) 11.0 57.0 n.a. c n.a. c n.a. c
Age at genetically confirmed diagnosis (d) 34.5 21.1 35.0 23.1 0.952
Note: Percentages are based upon available data for each variable.
Abbreviations: CF, cystic fibrosis; CFSPID, cystic fibrosis screen positive, inconclusive diagnosis; d, days; n.a., not available.
p-values smaller than 0.05 are highlighted in bold.
a Column percentages are given.
b p-value calculated from chi-square statistics comparing responders and non-responders.
c Information not available for non-responders.
d p-value calculated from two-sample mean-comparison test (t-test) comparing responders and non-responders.
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in Fig. 1).Some parents (n = 4) were dissatisfied with the brochure
because they felt it did not offer a good explanation of the
Legend
Information not received (or not read)
Not satisfied with the information
Satisfied with the information
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Info brochure Oral information Info at 
telephone
Info at hospital
Information from birth institution Information from CF-centre
69 77 100 124
12
30
24
12
55
21
12
Fig. 2. Parents' satisfaction with the information received throughout the screening process. Fig. 2 shows the satisfaction of parents with the information received at
different stages of the screening procedure. The numbers in the columns reflect the number of parents (N) within each category. Note: Percentages are based upon
available data for each variable. This figure was published in part before including fewer participants after 1 year of the implementation of the newborn screening for
CF in Switzerland (in Rueegg CS, et al. Deutsches Aerzteblatt International 2013; 110: 356–63 (Ref. [29])).
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the information (n = 2; Supplemental Table 3). Common
reasons for parental dissatisfaction with oral information given
at birth were that the screened diseases were not well explained
(n = 14), or that they would have liked more details (n = 9).
The 24 parents who were unsatisfied with the information they
received by phone said that the caller had not explained the test
result and the disease (n = 9), or had provided superficial
information and instead focused on arranging the appointment
(n = 5). Parents who were unhappy with the information they
received in the CF-centre wanted to be told more clearly that a
negative sweat test meant a healthy child (n = 3), or wished
they had been given more information at an earlier stage of
screening (n = 3).
In univariable logistic regression, we found that satisfaction
with the information received at birth (brochure and oral
information) was determined mainly by socio-demographic
factors. Parents of foreign origin and of a first child were more
dissatisfied (Supplemental Table 4).
The information received by telephone was less satisfactory
to parents of children diagnosed with a CF (OR 2.23, p =
0.044), or parents of younger infants (OR 0.93 per day older,
p = 0.001).Parents of a first child were more dissatisfied with the
information in the CF-centre (OR 0.21, p = 0.024).
3.4. Aim 3: determining the feelings of parents during the
screening process
Most parents (n = 98; 78%) were troubled or anxious after
the CF-centre called, but only 51 (38%) were still anxious after
the visit (Table 2; 19/88 families with a healthy child (21.6%)
and 32/48 families with a child with CF [66.7%; p b 0.001]).
Negative feelings after the phone call from the CF-centre
were more frequent in more highly educated parents (p =
0.003; Supplemental Table 5), and after a call from large
CF-centres (p = 0.005). Negative feelings after the visit in the
CF-centre were more often found in families of foreign origin
(p = 0.002) and if their infant had CF (p b 0.001).
3.5. Aim 4: parents' overall approval
Most parents (122 of 138; 88%) were glad that their child
had been screened: 84% (n = 75) of parents without CF
compared to 96% (n = 47) of families with CF (p = 0.103;
Table 2). Few parents gave specific reasons for their
Table 2
Parents' feelings during the screening and overall approval of the screening.
Overall Families without CF Families with CF
p-value b
n % a n %a n %a
Feelings during the screening procedure
Feeling after phonecall from CF-centre 0.445
Troubled & anxious 98 78 65 77 7 18
Calm & optimistic 27 22 20 24 33 82
Feeling after visit in the CF-centre b0.001
Troubled & anxious 51 38 19 22 32 67
Calm & optimistic 85 62 69 78 16 33
Approval of the screening
Families approve the screening 0.103
Yes 122 88 75 84 47 96
No 4 3 4 5 0 0
Not sure 12 9 10 11 2 4
Families would change something 0.625
Yes 53 45 36 46 17 42
No 66 55 42 54 24 58
Note: Percentages are based upon available data for each variable.
Abbreviations: CF, cystic fibrosis.
a Column percentages are given.
b p-value calculated from chi-square statistics comparing families with and without CF.
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who disapproved the screening and 40 families of 122 who
were in favour of the screening (Supplemental Table 6). Three
families stated that screening caused anxiety, and that theyTable 3
What parents would change about the national newborn screening for cystic
fibrosis, stratified by final CF diagnosis.
Whata parents of children with diagnosed CF would change (N=17)
In
fo
rm
at
io
n
pr
ov
is
io
n
• Better information about the screening and the diseases in the birth institution (n=3)
• More information about cystic fibrosis, also positive aspects and hope (n=3) 
• Inform parents directly about the screening result (n=2)
• Inform about Guthrie test before birth by gynaecologist or midwife (n=1)
• Written information about the disease and the meaning for relatives (n=1)
• Make sure the information brochure is really provided at birth (n=1)
Sc
re
en
in
g
pr
oc
ed
ur
e • Better communication among involved parties(birth hospital, CF-centre, paediatrician,
parents) (n=2)
• Shorter waiting time throughout the screening procedure (n=3)
• Nothing stated (n=1)
Whata parents of children without CF would change (N=36)
In
fo
rm
at
io
n 
pr
ov
is
io
n
• More detailed information from the birth institution about the Guthrie test and what a
positive screening result means (n=13)
• Inform already prior to birth, i.e. by gynaecologist (n=2)
• Better information at the telephone (that also healthy children (carriers) can have a positive
screening result; type ofdisease) (n=2)
• Better information why a 2nd Guthrie test is needed at the paediatrician (n=1)
• Give written information already after normal sweat test and not only after detailed genetic
analysis (n=1)
• Information at sweat test → state normal (healthy) results immediately (n=1)
• Tailor information to lay persons without using jargon (n=1)
Sc
re
en
in
g
pr
oc
ed
ur
e
• Whole coordination should be done by 1 central station, information gets faster to the family
and comes from known sources (i.e. paediatrician, gynaecologist) (n=4)
• Shorter waiting time throughout the screening procedure (n=3)
• Do not make a 2nd (or 3rd) Guthrie test but directly the sweat test (n=2)
• Improve the screening test to reduce false positives (n=2)
• Make the Guthrie test directly in the birth institution for immediate results (n=1)
• Give the possibility to make the sweat test in a place more close (n=1)
• Nothing stated (n=2)
Abbreviations: CF, cystic fibrosis; N, number; NBS, newborn screening.
a Parents could indicate in an open format question what they would change in
the CF newborn screening. Statements of the same meaning were manually
combined in this table.would have preferred not to know their child had CF so they
could enjoy the symptom-free time. Among parents who were
happy with the screening, 22 said that timely treatment
benefitted the child, nine were glad to know that their child
was healthy, four said that screening helps to avoid complica-
tions, two said that they always want to know if their child has a
disease, and two were glad to know that their child was a
carrier, in case the child showed symptoms later or will have
children.
Changes to the screening procedure were suggested by 45%
(n = 53) of parents (Table 2). Among families with a child with
CF (n = 17), most suggestions (n = 11) related to improving
the way information was provided (Table 3). Other comments
were related to the screening procedure, i.e. better communi-
cation among involved parties (n = 2), and shorter waiting
times throughout the screening procedure (n = 3). Among
families whose child did not have CF (n = 36), most
suggestions were again related to provision of information
(n = 21). Other suggestions concerned the screening procedure:
coordination over a central station (n = 4), shorter waiting time
(n = 3), reduction of false positives (n = 2), or conducting the
sweat test immediately, instead of repeating the heel-prick test
(n = 2).
4. Discussion
Most parents (78%) were troubled or anxious when they
were informed that the results of the screening test had been
positive, but only 22% of families without CF, and 67% with
CF, were still worried after the diagnostic evaluation. Overall,
most parents (88%) were satisfied with the screening irrespec-
tive of the final diagnosis (84% of parents without CF
compared to 96% of families with CF).
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The successful implementation of the CF-NBS programme
in Switzerland was attributable to the already well-established
nationwide NBS programme with its single, centralised
screening laboratory [29]. The opt-out procedure explains the
high participation rate in the screening. Our study is limited by
the fact that we have answers only from parents whose infants
had positive results on screening, and were then seen in a
CF-centre. We do not have information from parents recalled
for a second heel-prick test, for which the results were normal.
Furthermore, parent's feelings were assessed retrospectively,
after they had been given the final diagnosis. Therefore, their
emotional state when they completed the questionnaire might
have affected their recollections of past feelings. The study was
relatively small, and comments from individual parents should
not be given undue weight. Adapting the screening procedure
based on suggestions from the few parents who were not
pleased might lead to a decrease in satisfaction of the larger
group of parents who were happy with the current procedures.
4.2. Interpretation of the information provision and satisfaction
Consistent with the literature [15–17,20], we found that
well-informed parents are less stressed by the testing process.
All NBS programmes debate the amount of information that
should be given to new parents, who are already overloaded
with brochures. In Switzerland, the law on genetic screening
within the NBS has been in force since 2007, and all parents
must be told about the screening and their option to refuse, so a
chapter on ‘CF’ was added to the existing NBS brochure. It is,
however, possible that in daily life not all parents receive the
brochure; some might also not remember it. But if the children
of these parents would have been screened negative, they
would probably never have missed the information.
Some parents felt that details about the screening test and the
disease were missing when they were invited by phone for
diagnostic evaluation. But information provided during this
phone call is deliberately minimal without mentioning the
respective disease, so as to reduce parental anxiety and to
discourage parents from researching CF on the Internet before
they receive accurate information from a specialist.
4.3. Interpretation of parents' feelings
False-positive results and negative second heel-prick tests
are a challenge to every NBS programme, since they cause
parental anxiety and unnecessary medical examinations. When
children with positive screening results are tested in a
CF-centre, their parents often feel anxious or depressed while
awaiting definitive results [6,10]. A French study investigated
the short- and long-term psychological effects of false-positive
results in CF-NBS and found that 96.5% of parents were
anxious at the time of the sweat test [14]. However, 86% were
entirely reassured 3, 12, and 24 months after the test. In our
study, 78% of parents were troubled or anxious after the phone
call, but after the visit in the CF-centre, only 22% of thefamilies with a false-positive result were still troubled. Since we
only asked parents about their feelings once, shortly after
diagnostic evaluation in the CF-centre (median time to
questionnaire response 11 days, interquartile range 7–
24 days), we do not know the long-term effects of a
false-positive screening result.
Parents who were approached by larger CF-centres were
more anxious after the phone call. It is possible that a call from
a large university clinic might trigger more fear than a call from
a regional and more familiar hospital. Or it may also be possible
that calls from a large clinic that call more patients, may be less
personally accessible or reassuring. More educated parents
were more concerned after the phone call than less educated
parents, perhaps because more educated parents were more
aware of the potential consequences. We found that uncertainty
and stress persisted more in migrants, perhaps because of
language problems that may have prevented them from
understanding the information provided.
4.4. Interpretation of the overall satisfaction and implication
into practise
Overall, 88% of parents were glad that their child had been
screened, independent of final diagnosis. Nearly half of the
parents suggested that the screening programme could be
improved; most of them wished better information. This means
that the NBS brochure should be handed out more systemat-
ically, and that midwives or nurses responsible for giving the
oral information at the birth clinic might profit from special
training.
CF specialists should also be aware of the effect of the
information given by phone and in the CF-centres, since this
information can either reassure or cause anxiety to parents. The
period between informing parents about a positive screening
result (phone call) and their appointment at the CF-centre
should be as short as possible. Parents should only be called
when an appointment can be offered within the following days.
Many of the suggestions made by parents are already being
used to improve the screening process. For example, the Swiss
CF-NBS is trying to reduce false-positive screening results and
recalls for a 2nd heel-prick test by adding an additional
parameter: pancreatitis associated protein (PAP)-measurement
[31].
5. Conclusion
The large majority of families, independent of the child's
final CF diagnosis, were glad that their infants were screened,
and their suggestions to improve the process have already been
used to improve the screening procedure and this refinement
will be continued.
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